VERA (Vera Therapeutics, Inc.) Stock Financials & Earnings | Market Cap Arena

VERA (Vera Therapeutics, Inc.) Stock Financials & Earnings | Market Cap Arena

VERAVera Therapeutics, Inc.

Mkt Cap$3B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$0

Net Income (TTM)-$300M

EPS (TTM)-$4.66

Free Cash Flow (TTM)-$242M

Gross Margin—

Op. Margin—

Net Margin—

FCF Margin—

P/S Ratio (TTM)—

P/E Ratio (TTM)—

YoY Rev Growth—

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$0	$506K	-$31M
Q2 23	$0	$0	-$22M
Q3 23	$0	$0	-$22M
Q4 23	$0	$635K	-$27M
Q1 24	$0	$952K	-$31M
Q2 24	$0	$0	-$37M
Q3 24	$0	$0	-$50M
Q4 24	$0	$0	-$49M
Q1 25	$0	$0	-$57M
Q2 25	$0	-$563K	-$80M
Q3 25	$0	-$564K	-$84M
Q4 25	$0	$1M	-$94M

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 23	-$26M	-$26M
Q2 23	-$18M	-$18M
Q3 23	-$23M	-$23M
Q4 23	-$25M	-$25M
Q1 24	-$34M	-$34M
Q2 24	-$25M	-$25M
Q3 24	-$37M	-$62M
Q4 24	-$39M	-$40M
Q1 25	-$54M	-$55M
Q2 25	-$55M	-$55M
Q3 25	-$62M	-$62M
Q4 25	-$70M	-$70M

Capital Expenditures

CapEx

Quarter	CapEx
Q1 23	$0
Q2 23	$0
Q3 23	$0
Q4 23	$63K
Q1 24	$0
Q2 24	$89K
Q3 24	$25M
Q4 24	$645K
Q1 25	$187K
Q2 25	$208K
Q3 25	$133K
Q4 25	$102K

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 23	—	+83.6%
Q2 23	—	+45.9%
Q3 23	—	-13.8%
Q4 23	—	-19.5%
Q1 24	—	-0.5%
Q2 24	—	+70.0%
Q3 24	—	+128.9%
Q4 24	—	+81.0%
Q1 25	—	+83.8%
Q2 25	—	+114.6%
Q3 25	—	+68.5%
Q4 25	—	+92.6%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 23	$3M	—
Q2 23	$3M	—
Q3 23	$3M	—
Q4 23	$0	—
Q1 24	$4M	—
Q2 24	$5M	—
Q3 24	$6M	—
Q4 24	$6M	—
Q1 25	$8M	—
Q2 25	$9M	—
Q3 25	$10M	—
Q4 25	$11M	—

OpEx Breakdown

Quarter	R&D	G&A	S&M	SG&A
Q1 23	$26M	—	—	$6M
Q2 23	$16M	$6M	—	—
Q3 23	$16M	$6M	—	—
Q4 23	$22M	$6M	—	—
Q1 24	$25M	$8M	—	—
Q2 24	$29M	$8M	—	—
Q3 24	$40M	$9M	—	—
Q4 24	$33M	$16M	—	—
Q1 25	$41M	$15M	$1M	—
Q2 25	$58M	$22M	—	—
Q3 25	$56M	—	—	$27M
Q4 25	$60M	$35M	—	—

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$137M	$60M	$197M
Q2 23	$34M	$147M	$181M
Q3 23	$27M	$132M	$160M
Q4 23	$46M	$115M	$161M
Q1 24	$69M	$335M	$404M
Q2 24	$25M	$359M	$384M
Q3 24	$27M	$326M	$353M
Q4 24	$93M	$548M	$641M
Q1 25	$55M	$535M	$590M
Q2 25	$49M	$508M	$557M
Q3 25	$58M	$440M	$497M
Q4 25	$355M	$715M	$1.1B

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q1 23	38M	+35.5%
Q2 23	44M	+17.5%
Q3 23	44M	+0.2%
Q4 23	44M	+0.2%
Q1 24	51M	+14.7%
Q2 24	55M	+7.4%
Q3 24	55M	+0.3%
Q4 24	55M	+0.0%
Q1 25	64M	+16.0%
Q2 25	64M	+0.2%
Q3 25	64M	+0.1%
Q4 25	64M	+0.6%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 19	—	—
FY 20	—	—
FY 21	$0	17
FY 22	$0	46
FY 23	$0	51
FY 24	$0	112
FY 25	$0	75K